hypercalcaemia of malignancy
Oncology · 2016–2018
2decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zoledronic acid Multiple myeloma; bone metastases due to breast cancer or castration-resistant prostate cancer; hypercalcaemia of malignancy. | Jul 2018 | Recommended with restriction | no section in document |
| denosumab Treatment of hypercalcaemia of malignancy that is refractory to intravenous bisphosphonate treatment. | Mar 2016 | Not recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.